vs
渤健（BIIB）与Rivian Automotive, Inc.（RIVN）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是Rivian Automotive, Inc.的1.9倍（$2.5B vs $1.3B），渤健净利率更高（12.9% vs -63.1%，领先76.0%），渤健同比增速更快（2.0% vs -25.8%），渤健自由现金流更多（$594.3M vs $-1.1B），过去两年Rivian Automotive, Inc.的营收复合增速更高（3.3% vs 0.3%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
Rivian Automotive是2009年成立的美国电动汽车制造商及汽车科技企业，主打基于自研滑板平台打造的电动SUV、皮卡及EDV电动配送货车，旗下R1T皮卡于2021年末正式开启交付，还计划于2023年底前在美国和加拿大布局专属充电网络，其平台可适配新车型也可对外授权使用。
BIIB vs RIVN — 直观对比
营收规模更大
BIIB
是对方的1.9倍
$1.3B
营收增速更快
BIIB
高出27.8%
-25.8%
净利率更高
BIIB
高出76.0%
-63.1%
自由现金流更多
BIIB
多$1.7B
$-1.1B
两年增速更快
RIVN
近两年复合增速
0.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.5B | $1.3B |
| 净利润 | $319.5M | $-811.0M |
| 毛利率 | — | 9.3% |
| 营业利润率 | — | -64.8% |
| 净利率 | 12.9% | -63.1% |
| 营收同比 | 2.0% | -25.8% |
| 净利润同比 | 32.8% | -9.0% |
| 每股收益（稀释后） | $2.15 | $-0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBRIVN
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.3B | $1.3B | ||
| Q3 25 | $2.5B | $1.6B | ||
| Q2 25 | $2.6B | $1.3B | ||
| Q1 25 | $2.4B | $1.2B | ||
| Q4 24 | $2.5B | $1.7B | ||
| Q3 24 | $2.5B | $874.0M | ||
| Q2 24 | $2.5B | $1.2B |
净利润BIIBRIVN
| Q1 26 | $319.5M | — | ||
| Q4 25 | $-48.9M | $-811.0M | ||
| Q3 25 | $466.5M | $-1.2B | ||
| Q2 25 | $634.8M | $-1.1B | ||
| Q1 25 | $240.5M | $-545.0M | ||
| Q4 24 | $266.7M | $-744.0M | ||
| Q3 24 | $388.5M | $-1.1B | ||
| Q2 24 | $583.6M | $-1.5B |
毛利率BIIBRIVN
| Q1 26 | — | — | ||
| Q4 25 | 78.3% | 9.3% | ||
| Q3 25 | 73.4% | 1.5% | ||
| Q2 25 | 77.1% | -15.8% | ||
| Q1 25 | 74.1% | 16.6% | ||
| Q4 24 | 76.2% | 9.8% | ||
| Q3 24 | 74.1% | -44.9% | ||
| Q2 24 | 77.8% | -38.9% |
营业利润率BIIBRIVN
| Q1 26 | — | — | ||
| Q4 25 | -2.5% | -64.8% | ||
| Q3 25 | 22.0% | -63.1% | ||
| Q2 25 | 28.1% | -85.5% | ||
| Q1 25 | 12.8% | -52.8% | ||
| Q4 24 | 11.9% | -38.1% | ||
| Q3 24 | 18.3% | -133.8% | ||
| Q2 24 | 28.3% | -118.7% |
净利率BIIBRIVN
| Q1 26 | 12.9% | — | ||
| Q4 25 | -2.1% | -63.1% | ||
| Q3 25 | 18.4% | -75.3% | ||
| Q2 25 | 24.0% | -85.7% | ||
| Q1 25 | 9.9% | -44.0% | ||
| Q4 24 | 10.9% | -42.9% | ||
| Q3 24 | 15.8% | -125.9% | ||
| Q2 24 | 23.7% | -125.8% |
每股收益（稀释后）BIIBRIVN
| Q1 26 | $2.15 | — | ||
| Q4 25 | $-0.35 | $-0.66 | ||
| Q3 25 | $3.17 | $-0.96 | ||
| Q2 25 | $4.33 | $-0.97 | ||
| Q1 25 | $1.64 | $-0.48 | ||
| Q4 24 | $1.82 | $-0.67 | ||
| Q3 24 | $2.66 | $-1.08 | ||
| Q2 24 | $4.00 | $-1.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.4B | $6.1B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $18.7B | $4.6B |
| 总资产 | $29.5B | $14.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BIIBRIVN
| Q1 26 | $3.4B | — | ||
| Q4 25 | — | $6.1B | ||
| Q3 25 | — | $7.1B | ||
| Q2 25 | — | $7.5B | ||
| Q1 25 | — | $7.2B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | — | $6.7B | ||
| Q2 24 | — | $7.9B |
总债务BIIBRIVN
| Q1 26 | — | — | ||
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | $5.5B |
股东权益BIIBRIVN
| Q1 26 | $18.7B | — | ||
| Q4 25 | $18.3B | $4.6B | ||
| Q3 25 | $18.2B | $5.1B | ||
| Q2 25 | $17.6B | $6.1B | ||
| Q1 25 | $17.0B | $6.2B | ||
| Q4 24 | $16.7B | $6.6B | ||
| Q3 24 | $16.4B | $5.9B | ||
| Q2 24 | $15.9B | $6.8B |
总资产BIIBRIVN
| Q1 26 | $29.5B | — | ||
| Q4 25 | $29.4B | $14.9B | ||
| Q3 25 | $29.2B | $15.2B | ||
| Q2 25 | $28.3B | $15.6B | ||
| Q1 25 | $28.0B | $15.5B | ||
| Q4 24 | $28.0B | $15.4B | ||
| Q3 24 | $28.3B | $14.3B | ||
| Q2 24 | $26.8B | $15.4B |
负债/权益比BIIBRIVN
| Q1 26 | — | — | ||
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | 0.81× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-681.0M |
| 自由现金流经营现金流 - 资本支出 | $594.3M | $-1.1B |
| 自由现金流率自由现金流/营收 | 24.0% | -89.0% |
| 资本支出强度资本支出/营收 | — | 36.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $2.4B | $-2.5B |
8季度趋势，按日历期对齐
经营现金流BIIBRIVN
| Q1 26 | — | — | ||
| Q4 25 | $511.9M | $-681.0M | ||
| Q3 25 | $1.3B | $26.0M | ||
| Q2 25 | $160.9M | $64.0M | ||
| Q1 25 | $259.3M | $-188.0M | ||
| Q4 24 | $760.9M | $1.2B | ||
| Q3 24 | $935.6M | $-876.0M | ||
| Q2 24 | $625.8M | $-754.0M |
自由现金流BIIBRIVN
| Q1 26 | $594.3M | — | ||
| Q4 25 | $468.0M | $-1.1B | ||
| Q3 25 | $1.2B | $-421.0M | ||
| Q2 25 | $134.3M | $-398.0M | ||
| Q1 25 | $222.2M | $-526.0M | ||
| Q4 24 | $721.6M | $856.0M | ||
| Q3 24 | $900.6M | $-1.2B | ||
| Q2 24 | $592.3M | $-1.0B |
自由现金流率BIIBRIVN
| Q1 26 | 24.0% | — | ||
| Q4 25 | 20.5% | -89.0% | ||
| Q3 25 | 48.4% | -27.0% | ||
| Q2 25 | 5.1% | -30.5% | ||
| Q1 25 | 9.1% | -42.4% | ||
| Q4 24 | 29.4% | 49.4% | ||
| Q3 24 | 36.5% | -131.9% | ||
| Q2 24 | 24.0% | -89.6% |
资本支出强度BIIBRIVN
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 36.0% | ||
| Q3 25 | 1.8% | 28.7% | ||
| Q2 25 | 1.0% | 35.5% | ||
| Q1 25 | 1.5% | 27.3% | ||
| Q4 24 | 1.6% | 18.9% | ||
| Q3 24 | 1.4% | 31.7% | ||
| Q2 24 | 1.4% | 24.4% |
现金转化率BIIBRIVN
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.73× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 2.41× | — | ||
| Q2 24 | 1.07× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Product revenue, net | $1.8B | 71% |
| Royalty revenue on sales of OCREVUS | $317.2M | 13% |
| Contract manufacturing, royalty and other revenue | $246.9M | 10% |
| Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO | $94.7M | 4% |
| Alzheimer's collaboration Revenue | $59.5M | 2% |
| Other revenue from anti-CD20 therapeutic programs | $7.2M | 0% |
RIVN
| Automotive Segment | $839.0M | 65% |
| Software And Services Segment | $447.0M | 35% |
| Regulatory Credits | $30.0M | 2% |
